CION Ameerpet
Finishing chemotherapy is a strange kind of relief. The rhythm that structured your year stops, and what replaces it is a schedule of appointments spread weeks and then months apart. Knowing what that schedule is for — and what it cannot do — makes the waiting between visits far easier to hold.
When the last cycle is done, most women expect to feel triumphant and instead feel unmoored. The appointments that gave the year its shape disappear. What replaces them is a schedule of reviews spread weeks and then months apart, and it is rarely explained properly — which is why so many women arrive at each visit braced for a verdict that was never going to be delivered that day.
Follow-up runs three errands at once. It looks for signs that the cancer has come back, at a point where the next decision can be made calmly rather than in an emergency. It manages what treatment left behind — surgical menopause, neuropathy, fatigue, bowel and bladder changes. And where you are on maintenance therapy, it supervises that: blood counts, side effects, and whether the dose is still right for you.
The uncomfortable part, said plainly, is that surveillance after ovarian cancer does not prevent recurrence and does not, by itself, lengthen life. What it does is make sure that if the cancer returns, it is found in a clinic rather than an emergency department, characterised properly, and treated as part of a plan. That is genuinely worth having. It is not the same as protection, and you should not be told otherwise. The broader picture sits in our complete guide to ovarian cancer.
Watching for recurrence, managing the after-effects of surgery and chemotherapy, and supervising maintenance therapy. Most visits are mainly about the second and third.
Appointments sit closest together in the first two years, because that is when recurrence is most likely, then spread out as the years pass.
Anything new and persistent is a reason to be seen this week, not at the next scheduled slot. The schedule is a floor, not a ceiling.
Follow-up after ovarian cancer is deliberately front-loaded, and the shape of it is not arbitrary. Most recurrences of high-grade serous ovarian cancer occur within the first two to three years after platinum-based chemotherapy finishes, and the yearly risk falls steadily after that. Guidelines therefore recommend review roughly every two to four months for the first two years, every three to six months through years three to five, and annually thereafter — a schedule matched to where the risk actually sits rather than to a tidy calendar. It is also why being discharged from five-year follow-up is not the same as being told that symptoms no longer matter. Source: NCCN Clinical Practice Guidelines in Oncology — Ovarian Cancer; ESMO–ESGO consensus conference recommendations on ovarian cancer.
Guideline intervals, and what a visit at each stage usually contains. Your own schedule may sit tighter or looser depending on stage, what surgery achieved, and whether you are on maintenance therapy.
| Time since treatment finished | How often you are seen | What the visit usually includes |
|---|---|---|
| Years 1 and 2 | Every 2–4 months | History and examination, including a pelvic examination. CA-125 if it was raised at diagnosis. Review of maintenance therapy, blood counts and side effects. Imaging only if something prompts it. |
| Years 3 to 5 | Every 3–6 months | The same review, less often. Late effects — bone health, neuropathy, bowel and bladder function, menopausal symptoms, sleep and mood — take up more of the conversation as the years pass. |
| After 5 years | Once a year | Annual review with a low threshold for investigating anything new. Many women move to shared care with their gynaecologist or physician at this point. |
| If symptoms appear, at any stage | Within days, not at the next slot | Directed examination and, usually, a CT of the chest, abdomen and pelvis — rather than waiting for the schedule to come round. |
| If you carry a BRCA or other inherited variant | As above, plus a genetics review | Follow-up also covers breast surveillance and offering testing to relatives, arranged through genetic counselling. |
*These are guideline ranges, not rules. A visit brought forward because you are worried is a normal use of the system, not an imposition — and it is far better than three months of waiting and searching.
Follow-up visits are short, and they can feel oddly anticlimactic — a few questions, an examination, a blood form. Each part is doing specific work. Here is what each one is for.
Most recurrences are found because of what a woman says, not because of what a scan shows. Your oncologist is listening for a pattern: something new, that has lasted more than a couple of weeks, and that is not settling. Bloating that has come back. Pain that wakes you. A bowel habit that has changed and stayed changed. Appetite that has gone.
This is why it helps to arrive with a few date-stamped notes rather than trying to reconstruct three months from memory in a short slot. Two lines a week is enough. “I have not been myself” loses information; “bloating most days since the second week of April, worse in the evenings” does not.
An abdominal examination looks for distension, a mass, free fluid and any nodule in a scar or at the navel. A pelvic examination assesses the vault, where the uterus and ovaries were — a common site for disease to reappear, and one that neither blood tests nor conversation can assess.
It takes a couple of minutes, and many women find it the part they dread. It is also the part that finds things early enough to be dealt with straightforwardly, which is a reasonable trade for two minutes of discomfort.
If CA-125 was raised when you were diagnosed, it is usually measured at each visit and read as a trend rather than as a single number. A small fluctuation within the normal range means very little; a value climbing across two or three consecutive tests means something, and prompts a closer look. If your marker was never raised, following it adds nothing and it may not be tested at all.
What a rise does not do is start treatment automatically. It starts a conversation and, usually, a scan — and how quickly to act after that is a decision that belongs to you as much as to your oncologist.
Women often expect a scan at every visit and are unsettled when there is not one. In someone with no symptoms, a normal examination and a stable marker, routine scanning has not been shown to change outcomes, and repeated CT carries a real cumulative radiation dose. Guidelines therefore ask for imaging when there is something to explain, rather than as a reflex.
When a scan is warranted it is usually a CT of the chest, abdomen and pelvis, because that covers where ovarian cancer characteristically returns — the peritoneal surfaces, the omentum, lymph nodes and the space around the lungs. PET-CT is reserved for cases where conventional imaging is equivocal, and at CION it is arranged with a specialist partner centre.
If you are on maintenance treatment — PARP-inhibitor-class therapy, anti-angiogenic therapy, or hormonal treatment, depending on your tumour — a large part of each visit is about the treatment itself rather than about recurrence. Blood counts, blood pressure, fatigue, nausea, kidney and liver function: these decide whether the dose stays where it is.
Side effects are worth reporting even when they feel minor or embarrassing. Maintenance therapy works by being taken for a long time, and the commonest reason it stops early is an unreported side effect that could have been managed with a dose adjustment or a short break.
Surgery that removed both ovaries causes menopause immediately, and it is more abrupt than a natural one. Hot flushes, disrupted sleep, vaginal dryness, joint aches and low mood are common, and bone density falls faster after a surgical menopause — which is why bone health belongs in follow-up rather than as an afterthought. Numbness or burning in the fingers and toes after platinum-based chemotherapy can take many months to improve, and sometimes does not fully resolve.
None of this is a distraction from the cancer question. It is most of what determines how life actually feels for the next five years. Bring it up; there is usually something that can be done. There is more on the recovery timeline in our guide to life after ovarian cancer treatment.
The schedule assumes nothing changes in between. When something does, the schedule is the wrong instrument. Each of these earns a phone call, and some earn a hospital the same day.
The symptom that brought many women to diagnosis is also the commonest herald of relapse. New, persistent swelling deserves a scan, not reassurance.
Cramping pain with vomiting, or a bowel that has stopped working, can mean obstruction. Go to hospital the same day rather than waiting for a clinic slot.
Fluid can collect around a lung. New breathlessness on stairs or when lying flat should be assessed within days, not at the next visit.
Any new nodule in the abdominal wall, an old scar or the belly button should be examined promptly rather than watched for a few months.
One-sided leg swelling or calf pain can be a clot, which is commoner after ovarian cancer and after surgery. This needs same-day assessment.
Losing weight without trying, or losing your appetite for several weeks, is worth reporting even when everything else feels normal.
None of these means the cancer is back — infection, adhesions, anxiety and ordinary illness cause every one of them. Each simply earns an examination rather than a wait. If your bowel has stopped or you cannot breathe comfortably, go to an emergency department instead of waiting for a call back. How relapse behaves once it is confirmed is covered in platinum-sensitive versus platinum-resistant recurrence.
A 45-minute consultation to go through your treatment summary, your marker trend and the schedule you have been given — and to say plainly whether anything should change. Free, and open to women already in follow-up elsewhere.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring your discharge summary and your last few CA-125 results, and you will leave knowing what the schedule is doing for you.
It would be comforting to say that being watched closely keeps the cancer away. It does not. Surveillance detects; it does not prevent. And the evidence on detecting earlier is more sobering than most women are told: when a randomised trial compared starting chemotherapy on the strength of a rising CA-125 alone against waiting until symptoms appeared, the women treated earlier did not live longer, and they spent more of the time they had receiving treatment and its side effects.
That is not an argument for abandoning follow-up. It is an argument for being clear about what each part of it earns. The conversation and the examination earn a great deal — they find the obstructions, the effusions, the nodules and the manageable late effects. Marker testing earns lead time, which some women want for planning and others experience as months of feeling well being taken away. Routine scanning of a woman with no symptoms and a stable marker earns very little, which is precisely why guidelines do not ask for it.
There are situations where finding things sooner clearly changes the plan: a bowel beginning to obstruct, fluid collecting around a lung, or a single well-defined site of relapse in someone who responded well the first time and may be a candidate for further surgery. At CION that surgical assessment is coordinated with specialist gynaecologic-oncology surgeons at partner centres, and the decision comes from a tumour board looking at the whole picture rather than from a marker read in isolation.
Follow-up cannot stop a recurrence happening. What it can do is make sure one is found in a clinic, with time to plan, rather than in an emergency department at two in the morning.
Marker testing usually flags a relapse some months before symptoms. Some women want that time; others find it costs them months of feeling well. Both positions are reasonable, and you are allowed to say which is yours.
Threatened bowel obstruction, fluid around a lung, and a single resectable site of relapse are the situations where acting sooner changes what can be offered.
*If the intensity of surveillance is causing you more distress than reassurance, say so. Test frequency is adjustable, and a plan you can live with is worth more than one you dread.
Follow-up visits are short. Four small habits make the difference between a visit that reassures you and one that leaves you wondering what just happened.
Date and type of surgery, FIGO stage, histology and grade, the chemotherapy you had and how many cycles, any maintenance therapy, and your genetic test result. Keep a photo of it on your phone. It saves an hour in any emergency department and stops a new doctor guessing.
Two lines a week, dated: what started, how often, whether it settles. A pattern written down at the time carries weight; the same information reconstructed from memory in a five-minute slot usually does not survive the retelling.
The mind empties in a clinic room. Three written questions get answered; three remembered ones do not. If a scan or a result is due, ask directly when and how you will hear — uncertainty about that causes more sleepless nights than the results themselves.
Get the number for the day-care unit or nurse, and be clear about what counts as an emergency. Fatigue, sleep, sex, work and confidence recover more slowly than anyone warns — our guide to life after ovarian cancer treatment covers that side of it.
Follow-up is medical oncology work, and it is delivered in-house at CION: the clinic reviews and examinations, CA-125 and blood monitoring, maintenance therapy supervision, chemotherapy if the cancer returns, genetic counselling with BRCA and HRD testing where they are relevant, and nutrition and survivorship support alongside. Your first consultation is free and runs to about 45 minutes — long enough to go through a treatment summary and a marker trend properly, which is rather the point.
It runs across more than 35 centres in Telangana and Andhra Pradesh, and that matters more than it sounds. A schedule of visits every two to four months only works if each visit is realistically attendable. When every appointment is a day of travel to a city hospital, appointments start being skipped — usually the ones where nothing feels wrong, which are exactly the ones that keep the schedule honest. Being seen near home is not a convenience; it is what makes two years of follow-up survivable.
If the cancer does return and surgery is being considered, we will tell you plainly how that works here. Cytoreductive and other gynaecologic-oncology surgery, HIPEC and PET-CT are arranged with specialist partner centres and may be billed there, while your medical oncology care stays with us. Every case that raises a question goes to a tumour board rather than resting on one doctor’s judgement. And if you are already in follow-up elsewhere and simply want a second opinion on the plan you have been given, that is a legitimate reason to book — bring your discharge summary and your last few results, and ask our ovarian cancer specialists in Hyderabad what they would change.
Free, unhurried, and open to women already in follow-up elsewhere who want a second opinion on the schedule they have been given.
Clinic reviews, blood tests and maintenance-therapy monitoring across 35+ centres in Telangana and Andhra Pradesh, with specialist review sitting behind them.
A rising marker or an equivocal scan is discussed by medical oncology, imaging and pathology together — not decided by one clinician in a corridor.
What is done in-house and what is arranged at a partner centre is said upfront, before anything is booked. Decisions for healing, not billing.
Roughly every two to four months for the first two years, every three to six months through years three to five, and once a year after that. The schedule is front-loaded because most recurrences happen in the first two to three years. Your own intervals may differ: a woman on maintenance therapy is usually seen more often, because the treatment itself needs monitoring, while a woman five years out from an early-stage tumour may only need an annual review. Treat the schedule as a floor rather than a ceiling. If something new appears between appointments, being seen that week is the correct use of the system, not a nuisance to anyone.
Almost certainly not, and that is a clinical decision rather than a cost one. In a woman with no symptoms, a normal examination and a stable CA-125, routine scanning has not been shown to improve outcomes, and repeated CT carries a real cumulative radiation dose. Guidelines therefore ask for imaging when there is something to explain: new or persistent symptoms, an abnormal examination, or a confirmed rising marker. When a scan is warranted it is usually a CT of the chest, abdomen and pelvis, because that covers where ovarian cancer characteristically returns. PET-CT is kept for cases where conventional imaging is equivocal, and is arranged at a specialist partner centre.
Usually the first step is to repeat it rather than act on it. A single rise can come from infection, inflammation, recent surgery or ordinary laboratory variation, and the trend across two or three measurements says far more than one value. If the trend is genuinely climbing, your oncologist will examine you and usually arrange a scan to see whether there is anything visible to treat. What does not automatically follow is immediate chemotherapy. Randomised evidence found that starting treatment on a rising marker alone, before symptoms appeared, did not help women live longer and meant more months spent on treatment. When to act belongs in a proper conversation about what you want from that time.
Formal oncology follow-up usually runs for five years, after which many women move to annual review, often shared with their gynaecologist or physician. Ovarian cancer can return later than five years, so being discharged is not the point at which symptoms stop mattering: a new, persistent abdominal symptom in year seven deserves the same attention it would have had in year two. If you carry a BRCA or another inherited variant, follow-up does not really end, because breast surveillance continues and there are usually relatives who should be offered testing. Ask at your last scheduled visit exactly who to contact if something changes afterwards, and keep that number.
Usually yes, and it is worth arranging deliberately rather than assuming. CION runs more than 35 centres across Telangana and Andhra Pradesh, so clinic reviews, blood tests including CA-125, and maintenance-therapy monitoring can be done close to where you live, with tumour-board and specialist review still sitting behind those visits. This matters because a schedule of appointments every few months for two years only holds together if each one is realistically attendable. The visits women skip are the ones where nothing feels wrong, and those are precisely the ones that keep the schedule meaningful. Where a scan or a specialist procedure is needed, that part is arranged centrally or at a partner centre.
Anything new that lasts more than a week or two, and a few things immediately. Report bloating or abdominal swelling that has come back, pelvic or abdominal pain that does not settle, a change in bowel habit, unintended weight loss, a new lump in a scar or at the navel, or fatigue that is worsening rather than improving. Go to hospital the same day for cramping pain with vomiting or a bowel that has stopped working, for new breathlessness, or for a swollen painful leg. None of these means the cancer is back, since infection, adhesions and ordinary illness cause all of them, but each one earns an examination rather than a three-month wait.
The first consultation is free and runs to about 45 minutes, including if you are already in follow-up elsewhere and want a second opinion on the plan. CION delivers medical oncology in-house: follow-up clinics, CA-125 and blood monitoring, chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling and BRCA and HRD testing where they are relevant. Cytoreductive and other gynaecologic-oncology surgery, HIPEC and PET-CT are coordinated with specialist partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board.